Galmed Pharmaceuticals Ltd
GLMD
View Detailed Chart
0.880USD
+0.000+0.03%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
4.82MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.03%
5 Days
-3.82%
1 Month
+3.67%
6 Months
-52.42%
Year to Date
-72.40%
1 Year
-71.04%
View Detailed Chart
TradingKey Stock Score of Galmed Pharmaceuticals Ltd
Currency: USD Updated: 2025-12-24Key Insights
Galmed Pharmaceuticals Ltd's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 224/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 0.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Galmed Pharmaceuticals Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Hold
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Galmed Pharmaceuticals Ltd Highlights
StrengthsRisks
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Overvalued
The company’s latest PE is -0.26, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 75.58K shares, decreasing 17.58% quarter-over-quarter.
Galmed Pharmaceuticals Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Galmed Pharmaceuticals Ltd Info
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Ticker SymbolGLMD
CompanyGalmed Pharmaceuticals Ltd
CEOBaharaff (Allen)
Websitehttps://www.galmedpharma.com
FAQs
What is the current price of Galmed Pharmaceuticals Ltd (GLMD)?
The current price of Galmed Pharmaceuticals Ltd (GLMD) is 0.880.
What is the symbol of Galmed Pharmaceuticals Ltd?
The ticker symbol of Galmed Pharmaceuticals Ltd is GLMD.
What is the 52-week high of Galmed Pharmaceuticals Ltd?
The 52-week high of Galmed Pharmaceuticals Ltd is 3.610.
What is the 52-week low of Galmed Pharmaceuticals Ltd?
The 52-week low of Galmed Pharmaceuticals Ltd is 0.745.
What is the market capitalization of Galmed Pharmaceuticals Ltd?
The market capitalization of Galmed Pharmaceuticals Ltd is 4.82M.
What is the net income of Galmed Pharmaceuticals Ltd?
The net income of Galmed Pharmaceuticals Ltd is -7.52M.
Is Galmed Pharmaceuticals Ltd (GLMD) currently rated as Buy, Hold, or Sell?
According to analysts, Galmed Pharmaceuticals Ltd (GLMD) has an overall rating of Hold, with a price target of --.
What is the Earnings Per Share (EPS TTM) of Galmed Pharmaceuticals Ltd (GLMD)?
The Earnings Per Share (EPS TTM) of Galmed Pharmaceuticals Ltd (GLMD) is -3.436.
Related Instruments
+0.41%
+0.94%
+0.51%
+0.34%
-0.17%
+1.42%
+0.75%
+1.80%
+0.38%
+0.66%
+0.08%
+0.82%
+0.81%
+0.08%
+0.23%
-0.05%
-0.19%
0.00%
+1.54%
+0.50%Popular Symbols
